158602-35-8

Usage

Uses

Used in Pharmaceutical Industry:
1-Boc-3-azetidineacetic acid ethyl ester is used as a reagent for the synthesis of complex chemical entities, particularly in the development of new pharmaceuticals. Its Boc-protected azetidine structure provides a stable and versatile intermediate that can be further modified to create a wide range of medicinal compounds.
Used in Organic Chemistry Research:
1-Boc-3-azetidineacetic acid ethyl ester is used as an intermediate in the synthesis of various organic compounds. Its ethyl ester group and Boc-protected azetidine make it a valuable building block for researchers working on the development of new organic molecules with potential applications in various fields, including materials science and chemical engineering.

Upstream product

• 398489-26-4 tert-butyl 3-oxoazetidine-1-carboxylate 
• 1002355-96-5 tert-butyl 3-(2-ethoxy-2-oxoethylidene)azetidine-1-carboxylate 
• 183062-96-6 2-(1-(tert-butoxycarbonyl)azetidin-3-yl)acetic acid 

Downstream Products

• 712317-32-3 ethyl 2-(3-azetidinyl)acetate hydrochloride 
• 1332331-73-3 5-{[1-(cyclopropylcarbonyl)-3-azetidinyl]methyl}-4-[4-(1H-indazol-6-yl)phenyl]-2,4-dihydro-3H-1,2,4-triazol-3-one 
• 1332331-78-8 4-[4-(1-benzofuran-5-yl)phenyl]-5-{[1-(cyclopropylcarbonyl)-3-azetidinyl]methyl}-2,4-dihydro-3H-1,2,4-triazol-3-one 
• 183062-96-6 2-(1-(tert-butoxycarbonyl)azetidin-3-yl)acetic acid 
• 152537-03-6 tert-butyl 3-(2-hydroxyethyl)azetidine-1-carboxylate 

Relevant academic research and scientific papers

Intramolecular Ring-Opening Decomposition of Aryl Azetidines

The ring strain present in azetidines can lead to undesired stability issues. Herein, we described a series of N-substituted azetidines which undergo an acid-mediated intramolecular ring-opening decomposition via nucleophilic attack of a pendant amide group. Studies were conducted to understand the decomposition mechanism enabling the design of stable analogues.

5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES FOR TREATING NEUROLOGICAL AND NEURODEGENERATIVE DISEASES

The present invention provides, in part, compounds of Formula (I): or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N- oxide, wherein: R1, R2, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4- associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES

The present invention provides, in part, compounds of Formula I, or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N- oxide, wherein: (R1)a, (R2)b, (R3)c, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4- associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS

This invention relates to the use of triazolone derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of triazolones in the treatment of cancer.

Fibrinogen receptor antagonists for inhibiting aggregation of blood platelets

Fibrinogen receptor antagonists of the formula: STR1 are disclosed for use in inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets.